Agennix halts trial on mortality fears; Sucampo, Takeda see positive OBD data in study;

@FierceBiotech: CROs jump into 2012 with big contracting momentum. Article | Follow @FierceBiotech

@JohnCFierce: Interesting to see that AZ will retreat to Boston and Cambridge, U.K. as it downsizes neuro R&D. Less has been more for Boston. | Follow @JohnCFierce

@FierceMedDev: Vets used Bioptigen's Envisu R2300 system in the surgical removal of a cataract a 38-year-old African elephant. Release | Follow @FierceMedDev

@MarkHFierce: Alzheimer's spreads like an infection through a distorted protein. Columbia and Harvard made the finding. Huge. More | Follow @MarkHFierce

> Germany's Agennix AG halted enrollment and treatment in a Phase II/III study of talactoferrin in severe sepsis. The monitoring board made the recommendation after seeing that the 28-day mortality in the talactoferrin arm was greater than in the placebo arm. Agennix release

> Sucampo ($SCMP) and Takeda say they garnered positive data from the second late-stage study of the opioid-induced bowel dysfunction drug lubiprostone. The drug arm performed significantly better at spontaneous bowel movements versus the placebo group. Story

> Auxogyn, a Menlo Park, CA-based company advancing new technology for women's health, says it closed on the final tranche of its $20 million Series A from Kleiner Perkins, TPG Biotech, and Merck Serono Ventures. Auxogyn release

> Tranzyme Pharma ($TZYM) has garnered $9 million in debt financing. Story

Pharma News

@FiercePharma: Merck joins the select Big Pharma group that's reporting higher earnings and sales for Q4 and 2011--PR. Release | Follow @FiercePharma

> GSK resolves 20K more Avandia lawsuits, lawyer says. Item

> Merck's diabetes drugs offset Remicade sales decline. Report

> NICE rejects J&J's Zytiga as too expensive. Story

> AstraZeneca puts 7,300 jobs on the chopping block. News

Manufacturing News

> Roche plant spared from sale runs into GMP issues. More

> Pakistan drug manufacturers make plea for oversight. Story

> Amylin's OH plant prepped for Bydureon's U.S. debut. Article

Vaccines News

> Universal flu vaccine might be step closer. Story

> Study: Gardasil does not cause autoimmune disease. Article

> First hookworm vaccine enters clinical trials. More

> Ovarian cancer vaccine clinical trial begins enrollment. Item

> Evolving bacteria evade vaccines. Story

CRO News

> Lonza trouble may trigger big writedown at Ipsen. Article

> Pew pushes for better FDA oversight of global supply chain. More

> Analysts project red-hot Euro growth for CMO market. News

> Parexel plans more hires as it focuses on strategic players, biotech. Story

And Finally... New computer simulations demonstrate that a spider web's incredible durability depends not only on silk strength, but also on how the overall web design compensates for damage. Release

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.